Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study

被引：0

作者：

Aziz Zaanan

Juliette Palle

Emilie Soularue

Florence Leroy

Samy Louafi

David Tougeron

Sylvain Manfredi

Pascal Artru

Astrid Pozet

Julien Taieb

机构：

[1] European Georges Pompidou Hospital,Department of Gastroenterology and Digestive Oncology

[2] Assistance Publique-Hôpitaux de Paris,Department of Medical Oncology

[3] Paris Descartes University,Department of Gastroenterology and Digestive Oncology

[4] Sorbonne Paris Cité,Department of Cancer Medicine

[5] Saint Antoine Hospital,Department of Oncology

[6] Assistance Publique-Hôpitaux de Paris,Department of Gastroenterology

[7] Saint-Louis Hospital,Department of Gastroenterology and Digestive Oncology

[8] Assistance Publique-Hôpitaux de Paris,Department of Gastroenterology and Digestive Oncology

[9] Gustave Roussy Institute,Methodology and Quality of Life in Oncology Unit, INSERM UMR 1098

[10] Oncology Federation of Essonne,undefined

[11] Poitiers University Hospital,undefined

[12] Rennes University Hospital,undefined

[13] Jean Mermoz Hospital,undefined

[14] Besançon University Hospital,undefined

来源：

Targeted Oncology | 2018年 / 13卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：107 / 112

页数：5

共 50 条

[31] PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial
Hu, Xichun
Cao, Jun
Teng, Yue'e
Li, Hui-Ping
Zhang, Lili
Ouyang, Quchang
Xie, Weimin
Pan, Yueyin
Song, Zhenchuan
Ling, Xiaoling
Wu, Xiaohong
Xu, Jingwei
Li, Li
Ren, Liping
Wang, Hong
Zhou, Dongxian
Luo, Jing
CANCER RESEARCH, 2023, 83 (05)
[32] Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran
Farshid Farhan
Reza Ghalehtaki
Shiva Mahdavi-Seresht
Alipasha Meysamie
Maisa Yamrali
Borna Farazmand
Negin Mohammadi
Ehsan Saraee
Mohammad-Reza Mir
Ali Mir
Marzieh Lashkari
Samaneh Salarvand
Ebrahim Esmati
Farhad Samiei
Journal of Gastrointestinal Cancer, 2019, 50 : 907 - 912
[33] Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran
Farhan, Farshid
Ghalehtaki, Reza
Mandavi-Seresht, Shiva
Meysamie, Alipasha
Yamrali, Maisa
Farazmand, Borna
Mohammadi, Negin
Saraee, Ehsan
Mir, Mohammad-Reza
Mir, Ali
Lashkari, Marzieh
Salarvand, Samaneh
Esmati, Ebrahim
Samiei, Farhad
JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (04) : 907 - 912
[34] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Gavila, J.
De La Haba, J.
Bermejo, B.
Rodriguez-Lescure, A.
Anton, A.
Ciruelos, E.
Brunet, J.
Munoz-Couselo, E.
Santisteban, M.
Rodriguez Sanchez, C. A.
Santaballa, A.
Sanchez Rovira, P.
Garcia Saenz, J. a.
Ruiz-Borrego, M.
Guerrero-Zotano, A. L.
Huerta, M.
Cotes-Sanchis, A.
Lao Romera, J.
Aguirre, E.
Cortes, J.
Llombart-Cussac, A.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 420 - 428
[35] First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
Araki, Kazuhiro
Fukada, Ippei
Yanagi, Hiroyo
Kobayashi, Kokoro
Shibayama, Tomoko
Horii, Rie
Takahashi, Shunji
Akiyama, Futoshi
Ohno, Shinji
Ito, Yoshinori
BREAST, 2017, 35 : 78 - 84
[36] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
J. Gavilá
J. De La Haba
B. Bermejo
Á. Rodríguez-Lescure
A. Antón
E. Ciruelos
J. Brunet
E. Muñoz-Couselo
M. Santisteban
C. A. Rodríguez Sánchez
A. Santaballa
P. Sánchez Rovira
J. Á. García Sáenz
M. Ruiz-Borrego
A. L. Guerrero-Zotano
M. Huerta
A. Cotes-Sanchís
J. Lao Romera
E. Aguirre
J. Cortés
A. Llombart-Cussac
Clinical and Translational Oncology, 2020, 22 : 420 - 428
[37] A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).
Abali, Huseyin
Yalcin, Suayib
Onal, Huseyin Cem
Dane, Faysal
Oksuzoglu, Berna
Ozdemir, Nuriye
Mertsoylu, Huseyin
Artac, Mehmet
Camci, Celalettin
Karabulut, Bulent
Basal, Fatma Bugdayci
Budakoglu, Burcin
Sendur, Mehmet Ali Nahit
Goktas, Burce
Ozdener, Fatih
Calisgan, Arzu
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[38] The use of trastuzumab in Japanese patients with HER2-positive advanced or metastatic gastric cancer
Sawaki, A.
Ohashi, Y.
Omuro, Y.
Satoh, T.
Hamamoto, Y.
Boku, N.
Miyata, Y.
Takiuchi, H.
Ohtsu, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[39] Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.
Kashiwada, Tomomi
Saeki, Hiroshi
Uenosono, Yoshikazu
Makiyama, Akitaka
Iwatsuki, Masaaki
Narita, Yukiya
Satake, Hironaga
Matsuda, Yoshiko
Sonoda, Hideto
Oki, Eiji
Maehara, Yoshihiko
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study
Elisabeth S. Bergen
Lorenzo Pilla
Edouard Auclin
Aysegül Ilhan-Mutlu
Gerald W. Prager
Filippo Pietrantonio
Maria Antista
Filippo Ghelardi
Debora Basile
Giuseppe Aprile
Raffaella Longarini
Vincent Hautefeuille
David Tougeron
Pascal Artru
May Mabro
Antoine Drouillard
Gael Roth
Meher Ben Abdelghani
Inès Clement
Clemence Toullec
Laurent Mineur
Rosine Guimbaud
Julien Taieb
Aziz Zaanan
Gastric Cancer, 2023, 26 : 425 - 437

← 1 2 3 4 5 →